Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.35 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6837682 | 0.91 | GRIN1 (0.35) | GRIN1GRIN2BSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6837740 | 0.91 | SLC6A2 (0.42) | GRIN1GRIN2BSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6837755 | 0.90 | SLC6A2 (0.38) | GRIN1GRIN2BSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6838695 | 0.90 | SLC6A2 (0.32) | SLC6A2SLC6A4SLC6A3EPHA2 | |
| SCHEMBL6838542 | 0.89 | PIK3R1 (0.33) | SLC6A2SLC6A4SLC6A3EPHA2KDM4E | |
| SCHEMBL6837670 | 0.88 | HTR6 (0.34) | GRIN1GRIN2BSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6838090 | 0.87 | EPHA2 (0.34) | SLC6A2SLC6A4EPHA2 | |
| SCHEMBL6837686 | 0.86 | EGFR (0.41) | EGFRKDM4ELMNACYP1A2CYP3A4 | |
| SCHEMBL6838194 | 0.86 | EPHA2 (0.32) | EPHA2CYP3A4 | |
| SCHEMBL6837706 | 0.84 | ADORA3 (0.36) | SLC6A2SLC6A4SLC6A3EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1256582-A1 | 1H-IMIDAZOPYRIDINE DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | IL2, IL1A, IL4 | EGFR 1771/4885GRIN1 166/4885GRIN2B 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.